DNA甲基化iPLEX评估的发育亚型预测慢性淋巴细胞白血病自然史
研究开发了Me-iPLEX检测法,对来自4个独立队列的1286例CLL患者进行表观亚型分类,发现表观亚型可显著预测初诊患者的TTFT和OS,以及化学免疫治疗和伊布替尼治疗后的TTP和OS,且在调整IGHV突变状态和ZAP70表达后仍保持显著性。
要点
- Me-iPLEX可高通量定量多个独立位点的单CpG二核苷酸,将CLL样本分为3种已知表观亚型。
- 表观亚型显著预测初诊CLL患者的TTFT和OS,并在化学免疫治疗和伊布替尼治疗后预测TTP和OS。
- 表观亚型在按IGHV突变状态、ZAP70表达及其他常见预后标志物分层后仍保持显著性。
核心结论
- Me-iPLEX是一种可评估表观遗传特征的方法,能稳健分类CLL表观亚型,并在诊断和治疗时独立分层患者风险。
研究设计与样本
- 研究开发了Me-iPLEX检测法,用于高通量定量多个独立位点的靶向单CpG panel。
- 研究纳入来自4个独立队列的1286例CLL患者,代表CLL疾病病程和治疗的全面视图。
主要发现
- 表观亚型显著预测初诊CLL患者的TTFT和OS。
- 表观亚型预测化学免疫治疗和伊布替尼两种常见CLL治疗后的TTP和OS。
- 表观亚型在按IGHV突变状态、ZAP70表达及其他常见预后标志物分层后仍保持显著性。
- 在表观亚型间富集的生物学特征中,发现高度偏倚的免疫遗传学特征,包括中间程序化CLL表观亚型中IGLV3-21的使用。
临床怎么用
- Me-iPLEX可稳健分类CLL表观亚型,并在诊断和治疗时独立分层患者风险。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Alterations in global DNA methylation patterns are a major hallmark of cancer and represent attractive biomarkers for personalized risk stratification. Chronic lymphocytic leukemia (CLL) risk stratification studies typically focus on time to first treatment (TTFT), time to progression (TTP) after treatment, and overall survival (OS). Whereas TTFT risk stratification remains similar over time, TTP and OS have changed dramatically with the introduction of targeted therapies, such as the Bruton tyrosine kinase inhibitor ibrutinib. We have shown that genome-wide DNA methylation patterns in CLL are strongly associated with phenotypic differentiation and patient outcomes. Here, we developed a novel assay, termed methylation-iPLEX (Me-iPLEX), for high-throughput quantification of targeted panels of single cytosine guanine dinucleotides from multiple independent loci. Me-iPLEX was used to classify CLL samples into 1 of 3 known epigenetic subtypes (epitypes). We examined the impact of epitype in 1286 CLL patients from 4 independent cohorts representing a comprehensive view of CLL disease course and therapies. We found that epitype significantly predicted TTFT and OS among newly diagnosed CLL patients. Additionally, epitype predicted TTP and OS with 2 common CLL therapies: chemoimmunotherapy and ibrutinib. Epitype retained significance after stratifying by biologically related biomarkers, immunoglobulin heavy chain mutational status, and ZAP70 expression, as well as other common prognostic markers. Furthermore, among several biological traits enriched between epitypes, we found highly biased immunogenetic features, including IGLV3-21 usage in the poorly characterized intermediate-programmed CLL epitype. In summary, Me-iPLEX is an elegant method to assess epigenetic signatures, including robust classification of CLL epitypes that independently stratify patient risk at diagnosis and time of treatment.
引用
- Giacopelli B, Zhao Q, Ruppert AS, et al. Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. Blood. 2019. PMID: 31292113. doi:10.1182/blood.2019000490
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。